{
    "clinical_study": {
        "@rank": "13401", 
        "arm_group": [
            {
                "arm_group_label": "N1(traditional treatment group)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients in group N1 are treated with basic therapeutic measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature."
            }, 
            {
                "arm_group_label": "N2(midazolam group)", 
                "arm_group_type": "Experimental", 
                "description": "Patients in group N2 was treated with intravenous infusion of midazolam on the basis of basic treatment measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature."
            }
        ], 
        "brief_summary": {
            "textblock": "To explore the cerebral protective effect of midazolam in patients with traumatic brain\n      injury, we will collect blood samples from patients treated with or without midazolam when\n      the patient is admitted to ICU, 24 h, 48 h and 72 h after the admission before the use of\n      midazolam for patients in group N1, and before the patient is treated with midazolam, 24 h\uff0c\n      48 h, 72 h after the use of midazolam for patients in group N2. Parameters of cerebral\n      metabolism and inflammatory response will be obtained from the blood samples or the\n      cerebrospinal fluid. With the aforementioned parameters, the relationship between clinical\n      outcome and cerebral metabolism and inflammatory response will be detected with statistical\n      method."
        }, 
        "brief_title": "A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury", 
        "condition": "Traumatic Brain Injury", 
        "condition_browse": {
            "mesh_term": [
                "Brain Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged 18 or older;\n\n          -  Hospitalized in ICU within 6 hours after the injury or after the operation;\n\n          -  Traumatic brain injury is confirmed by computed tomography scan or magnetic resonance\n             imaging, Glasgow Coma Scale is 3 to 12, and the patient should meet the diagnostic\n             standard of severe traumatic brain injury;\n\n          -  Informed consent is obtained.\n\n        Exclusion Criteria:\n\n          -  Aged less than 18;\n\n          -  Death is expected in 24 hours;\n\n          -  History of neurological disease or history of drug abuse which may affect the outcome\n             of the study;\n\n          -  Failed to obtain Informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02071407", 
            "org_study_id": "2014021801"
        }, 
        "intervention": [
            {
                "arm_group_label": "N2(midazolam group)", 
                "description": "For patients allocated into group N2, 2 mg midazolam will be injected intravenously, and then it will be given at 0.05-0.1 mg/(kg\u00b7h) by intravenous infusion. If a surgery is needed, infusion of midazolam will begin 3 hours after the operation and continue for at least 72 hours. During the sedation with midazolam, BIS should be kept at 60 to 80.\nMorphine can be used to supply adequate analgesia.", 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "N1(traditional treatment group)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Midazolam"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "traumatic brain injury", 
            "sedation", 
            "midazolam"
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "contact": {
                "email": "rqzh7@yahoo.com.cn", 
                "last_name": "Ruiqiang Zheng, Doctor", 
                "phone": "18051060411"
            }, 
            "facility": {
                "address": {
                    "city": "Yangzhou", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "225001"
                }, 
                "name": "Subei People's Hospital of Jiangsu Province"
            }, 
            "investigator": {
                "last_name": "Ruiqiang Zheng, Doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "rqzh7@yahoo.com.cn", 
            "last_name": "Ruiqiang Zheng, Doctor", 
            "phone": "18051060411"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Chinese Medical Association", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "N1 group:  blood samples will be collected when the patient is admitted to ICU, 24 h, 48 h and 72 h after the admission\nN2 group: blood samples will be collected before the use of midazolam, 24 h, 48 h and 72 h after the use\nBlood sample will be collected every time from the radial artery and the jugular bulb separately. The blood sample will be used for blood gas analysis\nDetail parameters by blood test: levels of lactic acid, oxygen saturation(SaO2), partial pressure of oxygen(Pa02), jugular bulb venous oxygen saturation(SjvO2), jugular bulb oxygen partial pressure(PjvO2), hemoglobin(Hb)\nCalculated parameters: arterial oxygen content(Ca02), jugular venous oxygen saturation (SjvO2), arterial venous oxygen content difference(Da-jvO2), cerebral extraction of oxygen(CERO2), Lactate differences between jugular and arterial blood(AVDL) and Cerebral lactate acid production(CLP)", 
                "measure": "Cerebral metabolic parameters", 
                "safety_issue": "No", 
                "time_frame": "from the admission to ICU to 72 h after the admission for Group N1 and before the use of midazolam to 72 h after the use for group N2"
            }, 
            {
                "description": "N1: blood samples and cerebrospinal fluid are collected when the patient is admitted to ICU, 24 h, 48 h and 72 h after the admission\nN2: blood samples and cerebrospinal fluid are collected before the use of midazolam, 24 h, 48 h and 72 h after the use\nevery time, 3 ml blood sample will be collected from the jugular bulb and 2 ml  cerebrospinal fluid will be collected at the corresponding time\nThe blood sample will be anticoagulated by EDTA and then it will be centrifuged at 3000 r/min for 10 minutes within 30 minutes from the collection. The supernatant liquid will be stored in the freezer at -70\u2103.\nThe cerebrospinal fluid centrifuged at 3000 r/min for 10 minutes, and then the supernatant liquid will be stored in the freezer at -80\u2103.\nDetail parameters: sFkn and IL-6 levels of the blood sample and CSF will be tested 2 times by ELISA and then take the average.", 
                "measure": "Parameters of intracranial inflammatory response", 
                "safety_issue": "No", 
                "time_frame": "from the admission to ICU to 72 h after the admission for Group N1 and before the use of midazolam to 72 h after the use for group N2"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02071407"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Ramsay score", 
                "safety_issue": "Yes", 
                "time_frame": "from the use of midazolam to 72 h after the use for group N2"
            }, 
            {
                "measure": "seizure", 
                "safety_issue": "Yes", 
                "time_frame": "from the admission to ICU to 72 h after the admission"
            }, 
            {
                "measure": "one-week mortality", 
                "safety_issue": "Yes", 
                "time_frame": "from the admission to ICU to one week after the admission"
            }
        ], 
        "source": "Subei People's Hospital of Jiangsu Province", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Subei People's Hospital of Jiangsu Province", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}